18F-FLT Uptake at Baseline and 7 and 28 Days After Start of Treatment
| Parameter | Baseline | 7 d after start of treatment | 28 d after start of treatment | Friedman test P |
| Pharmacokinetic model | ||||
| K1 | 0.294 (0.242–0.389) | 0.255 (0.190–0.312) | 0.260 (0.193–0.424) | 0.11 |
| k3 | 0.129 (0.080–0.175) | 0.083 (0.069–0.123) | 0.088 (0.073–0.135) | 0.05 |
| BPND | 5.66 (3.27–8.21) | 3.12 (2.45–5.35) | 3.64 (2.61–6.06) | 0.02 |
| VB | 0.066 (0.050–0.128) | 0.082 (0.054–0.170) | 0.101 (0.065–0.171) | 0.001 |
| VT | 4.53 (3.12–5.52) | 3.41 (1.68–3.81) | 2.99 (2.60–3.79) | <0.001 |
| Ki | 0.063 (0.051–0.082) | 0.050 (0.031–0.058) | 0.048 (0.040–0.063) | 0.005 |
| Simplified models | ||||
| TBR PP 40–60 min | 5.0 (3.3–5.8) | 3.4 (1.8–4.6) | 3.5 (3.0–4.1) | 0.003 |
| TBR PP 50–60 min | 5.3 (3.3–5.8) | 3.5 (1.9–4.9) | 3.8 (3.2–4.4) | 0.001 |
| TBR WB 40–60 min | 4.3 (3.3–5.4) | 3.3 (2.0–4.4) | 3.4 (2.9–3.9) | 0.001 |
| TBR WB 50–60 min | 4.5 (3.3–5.8) | 3.5 (2.2–4.6) | 3.6 (3.1–4.1) | 0.001 |
| SUV LBM 40–60 min | 2.5 (2.0–3.3) | 1.9 (1.2–2.5) | 1.9 (1.6–2.2) | <0.001 |
| SUV LBM 50–60 min | 2.4 (2.0–3.2) | 1.9 (1.2–2.5) | 1.9 (1.6–2.2) | <0.001 |
BPND = nondisplaceable binding potential; VB = blood volume fraction; PP = parent plasma; WB = whole blood; LBM = lean body mass.
Data are median followed by interquartile range in parentheses.